During Tuesday’s Current trade, Shares of Dr Pepper Snapple Group Inc.(NYSE:DPS), gain 1.52% to $76.29.
Dr Pepper Snapple Group, Inc., (DPS) will issue its second quarter 2015 financial results on Thursday, July 23, before the market opens.
Larry Young, DPS president and CEO, and Marty Ellen, chief financial officer, will talk about the results during an earnings conference call for financial analysts and investors at 10 a.m. CDT that day. The conference call and slide presentation will be accessible live through the DPS website at http://www.drpeppersnapple.com and will be archived for replay for a period of 14 days.
Dr Pepper Snapple Group, Inc. operates as a brand owner, manufacturer, and distributor of non-alcoholic beverages in the United States, Canada, Mexico, and the Caribbean. The company operates through three segments: Beverage Concentrates, Packaged Beverages, and Latin America Beverages. It offers flavored carbonated soft drinks (CSDs) and non-carbonated beverages (NCBs), counting ready-to-drink teas, juices, juice drinks, water, and mixers.
Shares of Ameriprise Financial, Inc. (NYSE:AMP), declined -1.66% to $121.63, during its current trading session.
Ameriprise Financial, Inc. (AMP) released the results of the new Retirement 2.0SM study, revealing that the majority of Gen Xers (76%) report proactively planning for their retirement, with eight in 10 (79%) respondents presently saving through a 401(k) plan, and seven in 10 (69%) investing in an IRA or similar account.
The Retirement 2.0 study, which surveyed more than 1,500 Americans between the ages of 35-50 with at least $100,000 in investable assets, took a comprehensive look at how Gen X is approaching retirement. The study also explored how they have invested and saved for this major milestone; and how they expect to spend their retirement years. Encouragingly, the study found that Gen Xers began planning for retirement early and started saving at the average age of 26. They anticipate relying on their 401(k) accounts (42%) or IRAs (29%) as their main sources of income during retirement, while pensions (14%) and Social Security (5%) are predictable to take a back seat as primary sources of retirement funding.
Ameriprise Financial, Inc., through its auxiliaries, provides various financial products and services to individual and institutional clients in the United States and internationally. The company’s Advice & Wealth Administration segment provides financial planning and advice, in addition to full-service brokerage services primarily to retail clients through its advisors. Its Asset Administration segment offers investment advice and investment products to retail, high net worth, and institutional clients through unassociated third party financial institutions and institutional sales force. This segment’s products comprise U.S. mutual funds and their non-U.S. equivalents, exchange-traded funds, variable product funds underlying insurance, and annuity separate accounts; and institutional asset administration products, such as traditional asset classes, separately managed accounts, individually managed accounts, collateralized loan obligations, hedge funds, collective funds, and property funds.
RXi Pharmaceuticals Corp(NASDAQ:RXII), during its Tuesday’s current trading session decreased -5.94% to $0.510.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Finally, Clean Energy Fuels Corp(NASDAQ:CLNE), decreased -1.91%, to $5.13.
Clean Energy Fuels Corp. (CLNE) declared it will release financial results for the second quarter of 2015 on Wednesday, August 5, 2015 after market close, followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific). President and Chief Executive Officer of Clean Energy Andrew J. Littlefair and Chief Financial Officer Bob Vreeland will host the call.
Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets in the United States and Canada. It designs, builds, operates, and maintains fueling stations; and supplies compressed natural gas (CNG) fuel for light, medium, and heavy-duty vehicles, in addition to liquefied natural gas (LNG) fuel for medium and heavy-duty vehicles.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
